PMC:7381711 / 746-1000 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T4","span":{"begin":30,"end":37},"obj":"Body_part"},{"id":"T5","span":{"begin":234,"end":241},"obj":"Body_part"}],"attributes":[{"id":"A4","pred":"fma_id","subj":"T4","obj":"http://purl.org/sig/ont/fma/fma82839"},{"id":"A5","pred":"fma_id","subj":"T5","obj":"http://purl.org/sig/ont/fma/fma82839"}],"text":"orting the therapeutic use of heparin, both unfractionated and low molecular weight, as an anticoagulant for the treatment of SARS-CoV-2 infection. Additionally, we review preclinical evidence establishing biological plausibility for heparin and syntheti"}

{"project":"LitCovid-PubTator","denotations":[{"id":"28","span":{"begin":30,"end":37},"obj":"Chemical"},{"id":"29","span":{"begin":234,"end":241},"obj":"Chemical"},{"id":"38","span":{"begin":126,"end":146},"obj":"Disease"}],"attributes":[{"id":"A28","pred":"tao:has_database_id","subj":"28","obj":"MESH:D006493"},{"id":"A29","pred":"tao:has_database_id","subj":"29","obj":"MESH:D006493"},{"id":"A38","pred":"tao:has_database_id","subj":"38","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"orting the therapeutic use of heparin, both unfractionated and low molecular weight, as an anticoagulant for the treatment of SARS-CoV-2 infection. Additionally, we review preclinical evidence establishing biological plausibility for heparin and syntheti"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T12","span":{"begin":126,"end":134},"obj":"Disease"},{"id":"T13","span":{"begin":126,"end":130},"obj":"Disease"},{"id":"T14","span":{"begin":137,"end":146},"obj":"Disease"}],"attributes":[{"id":"A12","pred":"mondo_id","subj":"T12","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A13","pred":"mondo_id","subj":"T13","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A14","pred":"mondo_id","subj":"T14","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"}],"text":"orting the therapeutic use of heparin, both unfractionated and low molecular weight, as an anticoagulant for the treatment of SARS-CoV-2 infection. Additionally, we review preclinical evidence establishing biological plausibility for heparin and syntheti"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T3","span":{"begin":30,"end":37},"obj":"Chemical"},{"id":"T4","span":{"begin":91,"end":104},"obj":"Chemical"},{"id":"T5","span":{"begin":234,"end":241},"obj":"Chemical"}],"attributes":[{"id":"A3","pred":"chebi_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/CHEBI_28304"},{"id":"A4","pred":"chebi_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/CHEBI_50249"},{"id":"A5","pred":"chebi_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/CHEBI_28304"}],"text":"orting the therapeutic use of heparin, both unfractionated and low molecular weight, as an anticoagulant for the treatment of SARS-CoV-2 infection. Additionally, we review preclinical evidence establishing biological plausibility for heparin and syntheti"}